CurrentUnitedHealthcarePolicy N/A

Authorization form and coverage criteria for medications to treat active systemic lupus nephritis (ISN/RPS Class III/IV ± V)

Form and criteria used to request initial or re-authorization of a medication for beneficiaries with active systemic lupus nephritis (ISN/RPS Class III/IV ± V), including required clinical data and prescriber attestation; affects prescribers requesting coverage.

Policy Summary

PayerUnitedHealthcare

PolicyAuthorization form and coverage criteria for medications to treat active systemic lupus nephritis (ISN/RPS Class III/IV ± V)

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionComplete the prior authorization form with biopsy-proven ISN/RPS Class III or IV (± V), UPCR, baseline eGFR and BP, prescriber signature, and attach current progress notes.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

15total questionnaire items

12initial authorization

3re-authorization

ISN/RPS III/IV ± Vrequired diagnosis

>=18age requirement queried

Coverage Criteria

Initial Authorization

Covered when ALL of the following are met:

Initial Authorization: 1) Beneficiary has a diagnosis of active systemic lupus nephritis.

Corresponds to form question 1.

2) Biopsy-proven ISN/RPS active Class III or IV lupus nephritis alone or in combination with Class V.

Corresponds to form question 2 requesting ISN/RPS biopsy-proven Class III or IV ± V.

3) Provide the beneficiary's urine protein-to-creatinine ratio (UPCR).

Corresponds to form question 3.

4) Beneficiary is age 18 or older.

Corresponds to form question 4 (age queried).

Policy Summary

PayerUnitedHealthcare

PolicyAuthorization form and coverage criteria for medications to treat active systemic lupus nephritis (ISN/RPS Class III/IV ± V)

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionComplete the prior authorization form with biopsy-proven ISN/RPS Class III or IV (± V), UPCR, baseline eGFR and BP, prescriber signature, and attach current progress notes.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

5) No hypersensitivity to any component of the medication.

Corresponds to form question 5.

6) Medication is not being administered with strong CYP3A4 inhibitors (or concomitant use is documented and addressed).

Corresponds to form question 6 (examples: ketoconazole, itraconazole, clarithromycin).

7) No severe hepatic impairment (or severe hepatic impairment is documented and addressed).

Corresponds to form question 7.

8) Medication is being given with background immunosuppressive therapy (excluding cyclophosphamide) — document concomitant therapy.

Corresponds to form question 8.

9) Baseline blood pressure documented.

Corresponds to form question 9.

10) Baseline renal function (eGFR) documented.

Corresponds to form question 10.

11) Plan to assess renal function (eGFR) at regular intervals confirmed.

Corresponds to form question 11.

12) Medication prescribed by or in consultation with a rheumatologist; prescriber signature and attached progress notes provided.

Combines form question 12 and mandatory prescriber signature/progress notes requirement.

Re-authorization

Covered on re-authorization when ALL of the following are met:

Re-authorization: 13) Beneficiary continues to meet the initial authorization criteria (questions 1-12).

Corresponds to form question 13.

14) Beneficiary demonstrates disease improvement and/or stabilization or improvement in the slope of decline.

Corresponds to form question 14.

15) No treatment-restricting adverse effects (e.g., hypertension, neurotoxicities, hyperkalemia); attach current progress notes documenting disease status and clinical response; prescriber signature on file.

Corresponds to form question 15 and the instruction to attach progress notes and prescriber signature.

Coverage determinations require documentation that the beneficiary has biopsy‑proven ISN/RPS active Class III or IV lupus nephritis (alone or with Class V). The prior‑authorization form explicitly requests the ISN/RPS biopsy result, urine protein‑to‑creatinine ratio (UPCR), baseline blood pressure and eGFR, documentation that renal function will be monitored, prescriber specialty/consultation, and prescriber signature with attached progress notes. Failure to provide these items may prevent authorization because the form is designed to confirm active, biopsy‑proven disease and appropriate baseline and monitoring data.

For authorization purposes, treatment is considered not medically necessary when the beneficiary does not have a documented ISN/RPS biopsy showing active Class III or IV lupus nephritis (with or without Class V). The form also requires addressing contraindications such as hypersensitivity to medication components, concomitant strong CYP3A4 inhibitors, and severe hepatic impairment; if these issues are present and not addressed in the documentation, approval may be denied.

Coding and Patient Eligibility

Age

Age requirementBeneficiary is age 18 or older (queried on the form)

Form item numberQuestion 4 on the initial authorization form asks if beneficiary is age 18 or older

Impact on coverageAge >= 18 is required for authorization per the form criteria

Provider Actions and Documentation Requirements

Prior Authorization

Prior Authorization Form Completion

Prior authorization requests must include a completed prior authorization form. The form must document a biopsy-proven diagnosis of active systemic lupus nephritis (ISN/RPS Class III or IV alone or combined with Class V) and answer all initial authorization questions (1–12). Incomplete forms may delay review.

Form question 2: ISN/RPS biopsy-proven active Class III or IV ± Class V Lupus Nephritis required
Form must include answers to questions 1–12 for initial authorization

Note

Concomitant Immunosuppression Query

The prior authorization form asks whether the beneficiary is receiving concomitant background immunosuppressive therapy. Document presence or absence of background immunosuppression; note that cyclophosphamide is excluded from this question.

Form question 8: Is the beneficiary concomitantly receiving background immunosuppressive therapy? (excluding cyclophosphamide)
If yes, specify agents, doses, and start dates in supporting documentation

Documentation Required

Required Supporting Documentation

Attach required supporting documentation with the prior authorization request. Failure to provide the following may result in denial or request for additional information.

Progress notes documenting diagnosis, biopsy report confirming ISN/RPS class, and clinical status
Baseline and current urine protein-to-creatinine ratio (UPCR)
Baseline and current estimated glomerular filtration rate (eGFR)
Baseline blood pressure readings and documentation of blood pressure management
Documentation of concomitant immunosuppressive medications (if applicable) with doses and dates
Medication history including hypersensitivity/allergy information
Assessment of hepatic function and any use of strong CYP3A4 inhibitors
For re-authorization: documentation of continued benefit, disease improvement/stabilization, and any treatment-restricting adverse effects

Denial Risk

Documentation and Criteria Gaps

Provide complete, accurate, and legible documentation. Omissions — such as missing biopsy confirmation, absent UPCR or eGFR values, no documentation of concomitant immunosuppression, or unsigned prescriber attestation — may lead to denial or a request for additional information and will delay authorization.

Unsigned prescriber signature will render the request incomplete (Prescriber Signature Mandatory)
Re-authorization requires answers to questions 13–15 and attached current progress notes
Be prepared to provide interval lab values and blood pressure monitoring if requested

Background

This authorization form applies to medications used to treat active systemic lupus nephritis and is intended specifically for beneficiaries with biopsy‑proven ISN/RPS Class III or IV lupus nephritis, alone or in combination with Class V. The form collects disease‑activity measures (UPCR), baseline kidney function (eGFR), blood pressure, concomitant background immunosuppression (excluding cyclophosphamide), and requires that the medication be prescribed by or in consultation with a rheumatologist to support the request.

Definitions

ISN/RPS Class III/IV Lupus Nephritis

DefinitionBiopsy-proven active Class III or IV lupus nephritis, alone or in combination with Class V, as defined by the International Society of Nephrology/Renal Pathology Society (ISN/RPS)

Form item numberQuestion 2 on the initial authorization form requests ISN/RPS biopsy documentation of active Class III or IV ± Class V

Documentation requiredAttach biopsy report confirming ISN/RPS class to support authorization

UPCR

DefinitionUrine protein to creatinine ratio (UPCR) — numeric value to assess proteinuria

Form item numberQuestion 3 on the initial authorization form requests the beneficiary's UPCR value

PurposeUPCR is collected to document disease activity and inform authorization decisions